In women, this may lead to a feeling of fullness or a modest increase in breast size, although this is not a universal side effect and is typically mild. She adds that, in most cases, any breast enlargement associated with spironolactone improves or resolves once the medication is discontinued
Darsalia V, Larsson M, Nathanson D, Klein T, Nystrom T, Patrone C
While both are frequently referenced in similar research areas, they differ in their mechanisms and primary areas of investigation
2 We dont yet have long-term trials on the newest GLP medications like tirzepatide, which targets two metabolic pathways instead of one but early data suggest potentially even bigger reductions in both serious cardiac events and overall mortality
Changes in weight bias and perceived employability following weight loss and gain
doi:10.1007/s40572-023-00402-x